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RESEARCH ARTICLE Open Access
N-terminal pro-B-type natriuretic peptide
and microsize myocardial infarction risk in
the reasons for geographic and racial
differences in stroke study
Madeline R. Sterling1*, Raegan W. Durant2, Joanna Bryan1, Emily B. Levitan3, Todd M. Brown4, Yulia Khodneva2,
Stephen P. Glasser5, Joshua S. Richman6, George Howard7, Mary Cushman8 and Monika M. Safford1
Abstract
Background: N-terminal pro B-type peptide (NT-proBNP) has been associated with risk of myocardial infarction (MI)
, but less is known about the relationship between NT-proBNP and very small non ST-elevation MI, also known as
microsize MI. These events are now routinely detectable with modern troponin assays and are emerging as a large
proportion of all MI. Here, we sought to compare the association of NT-proBNP with risk of incident typical MI and
microsize MI in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
Methods: The REGARDS Study is a national cohort of 30,239 US community-dwelling black and white adults aged
≥ 45 years recruited from 2003 to 2007. Expert-adjudicated outcomes included incident typical MI (definite/
probable MI with peak troponin ≥ 0.5 μg/L), incident microsize MI (definite/probable MI with peak troponin < 0.
5 μg/L), and incident fatal CHD. Using a case-cohort design, we estimated the hazard ratio of the outcomes as a
function of baseline NT-proBNP. Competing risk analyses tested whether the associations of NT-proBNP differed
between the risk of incident microsize MI and incident typical MI as well as if the association of NT-proBNP differed
between incident non-fatal microsize MI and incident non-fatal typical MI, while accounting for incident fatal
coronary heart disease (CHD) as well as heart failure (HF).
Results: Over a median of 5 years of follow-up, there were 315 typical MI, 139 microsize MI, and 195 incident fatal
CHD. NT-proBNP was independently and strongly associated with all CHD endpoints, with significantly greater risk
observed for incident microsize MI, even after removing individuals with suspected HF prior to or coincident with
their incident CHD event.
Conclusion: NT-proBNP is associated with all MIs, but is a more powerful risk factor for microsize than typical MI.
Keywords: Coronary heart disease, B-type natriuretic peptide, Mircosize myocardial infarction, Racial disparities,
Cohort study
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Background
B-type natriuretic peptide (BNP) and its N-terminal frag-
ment (NT-proBNP) are cardiac-derived secretory hormones
with diuretic, vasodilatory, and natriuretic properties [1].
Although it is commonly used in assessing patients with
heart failure (HF), NT-proBNP is independently associated
with risk of coronary heart disease (CHD) as well as adverse
outcomes among patients with ST-elevation myocardial
infarction (STEMI). [2–5] Recently, the prognostic implica-
tions of NT-proBNP have been extended to patients with
non–ST-elevation MI (NSTEMI) and those with stable
CHD presenting with chest pain [6, 7].
While NT-proBNP is associated with MI in general, less
is known about the relationship between NT-proBNP and
the emerging disorder of very small NSTEMI, or micro-
size MI. Microsize MI has modest peak troponin eleva-
tions that in the past were considered to have uncertain
clinical relevance [8]. Because of the wide implementation
of sensitive troponin assays, microsize MIs are now in-
creasingly recognized and have been shown to be associ-
ated with elevated long term CHD risk [8, 9]. A better
understanding of the similarities and differences in risk
factors between microsize and typical MIs is needed to
guide risk stratification and optimize clinical management
[10–13].
Prior to the widespread use of highly sensitive tropo-
nin assays, studies demonstrated an association of NT-
proBNP with the incidence of typical MIs, but were lim-
ited in the ability to differentiate typical from microsize
MIs. Therefore, we hypothesized that there would be an
association between baseline levels of NT-proBNP and
risk of incident microsize MIs. We conducted this study
in the national Reasons for Geographic and Racial Dif-
ferences in Stroke (REGARDS) cohort study.
Methods
REGARDS cohort study procedures
Details of the REGARDS study have been described pre-
viously [14]. Briefly, REGARDS is a prospective cohort
study evaluating racial and geographic disparities in
stroke and MI. 30,239 English-speaking, community
dwelling U.S. adults ≥ 45 years of age were recruited be-
tween January 2003 and October 2007 by mail and tele-
phone. Blacks and residents of the stroke belt were
oversampled [14]. Participants completed a telephone
interview ascertaining medical history followed by an in-
home examination assessing blood pressure levels, height
and weight, ECGs, anthropomorphic measures, and blood
and urine samples along with a medication inventory.
Blood and urine samples were processed at the REGARDS
Central Laboratory at the University of Vermont. Phlebot-
omy was performed by trained personnel after a 10–12 h
fast, using standardized procedures. Within 2 h of collec-
tion, samples were centrifuged and shipped on ice to the
University of Vermont, where, upon arrival, samples were
centrifuged at 30,000 × G and 4 °C, and either analyzed
(general chemistries) or stored at − 80 °C [15, 16].
At six month intervals, participants are contacted by
phone to ask about hospitalizations and general health
status, with medical record retrieval for suspected cor-
onary events. The study protocol was reviewed and ap-
proved by the University of Alabama at Birmingham
Institutional review board and all participants provided
written informed consent.
Primary outcome(s)
For CHD events, medical records were adjudicated by ex-
pert clinicians based on published guidelines [17, 18] con-
sidering clinical signs and symptoms consistent with
ischemia; a rising and/or falling pattern of troponin over
≥ 6 h with a peak at least twice the upper limit of normal;
and/or ECG or other imaging findings consistent with is-
chemia based on the Minnesota code [19]. Cases where
the clinical presentation was equivocal or where the
troponin rise was less than twice the upper limit of normal
were adjudicated to be possible MIs and were not in-
cluded as outcomes in this analysis. Cases with low-level
troponin elevations without a rising and/or falling pattern
over ≥ 6 h or with a non-ischemic cause of troponin eleva-
tion were not considered to be MIs. Elective and urgent
coronary revascularization procedures were not included
in the definition of MI and we classified MIs caused by an
invasive procedure as procedure related. Only definite or
probable MIs were considered as MIs. Definite MIs in-
cluded cases with diagnostic enzymes or electrocardio-
gram and probable MIs included cases with elevated but
not diagnostic (ie, equivocal) enzymes with a positive but
not diagnostic electrocardiogram or, if enzymes were
missing, a positive electrocardiogram in the presence of is-
chemic signs or symptoms.
As other REGARDS studies have done, 0.5 μg/L was
used as the threshold of peak troponin to define micro-
size MI [20, 18]. This definition of microsize MI (peak
troponin < 0.5 μg/L) has been previously used by Safford
et al. (2013) and is based on clinical practice as well as
an analyses of troponin assay 99th percentiles and 10%
CV levels available on the International Federation of
Clinical Chemists website [21]. All other adjudicated
definite or probable MIs were considered to be typical
MIs (peak troponin ≥ 0.5 μg/L) [20, 21].
Since death at the first presentation with CHD remains
common, an additional endpoint included total incident
fatal CHD (deaths caused by CHD including sudden
deaths and death within 28 days of an adjudicated MI). In-
terviews with next of kin, the National Death Index, [14]
death certificates, medical records, and autopsy reports
were used to adjudicate cause of death.
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NT-proBNP
Baseline NT-Pro BNP was measured using the Roche
Elecsys analyzer (Roche Diagnostics Indianapolis, IN)
which utilizes an electrochemiluminescence immuno-
assay (inter-assay coefficient of variation < 5%) [22].
Covariates
Demographic data included self-reported age, sex, race
(black or white), education (less than high school and high
school or higher), annual income (less than $20,000 and
$20,000 and above). Region of residence was classified as
being a resident of the stroke buckle (the coastal regions
of North and South Carolina and Georgia), the stroke belt
(the remainder of North and South Carolina and Georgia,
plus Alabama, Mississippi, Louisiana, Arkansas, and
Tennessee), or not a stroke belt resident (the remaining
40 contiguous United States). Clinical CHD risk factors
included diabetes, defined as fasting blood glucose
≥126 mL/dL (or glucose > 200 mL/dL for those failing to
fast) or oral hypoglycemic or insulin use; systolic blood
pressures based on the average of 2 standardized blood
pressure measurements (continuous variables in mm Hg);
body mass index (BMI) based on measured height and
weight; cigarette smoking (current smoking versus never
or former smokers); albumin-to-creatinine ratio (ACR),
which was log transformed for the analysis; high sensitivity
c-reactive protein (hsCRP), which was also log trans-
formed; and high-density lipoprotein (HDL) and total
cholesterol. Estimated glomerular filtration rate (eGFR)
was calculated using the Chronic Kidney Disease (CKD)
Epidemiology Collaboration formula, [23] with CKD de-
fined as eGFR as < 60 ml/min/1.73 [2]. Medication use in-
cluded aspirin (yes or no), statins (yes or no), and
antihypertensive medications (yes or no).
Case-cohort design
The case-cohort study design minimizes the cost of ex-
pensive biomarker assays without compromising the
power advantage of large cohort studies [24, 25]. Here,
the study was comprised of all incident acute CHD cases
through 12/31/2010 and a stratified random sample of
participants free of CHD at baseline and not on dialysis
(the sub-cohort). The sub-cohort random sample was
selected as previously described using stratified random
sampling in 20 age (45–54, 55–64, 65–74, 75–84, ≥
85 years), race (black and white), and sex strata [26].
Statistical analysis
Participant characteristics were compared across tertiles
of NT-proBNP within the cohort random sample using
appropriate sampling weights. Analysis of variance and
Χ2 tests were used to evaluate significant differences.
Using Cox regression for case-cohort studies, [25] with
Barlow and Prentice sampling weights, [27] we performed
competing risk analyses as described by Lunn and McNeil
[28] incorporating the sub-cohort sampling weights to test
whether the association between NT-proBNP and the risk
of incident microsize MI differed from 1) that of typical
MI and 2) while also accounting for incident fatal CHD
death. Hazard ratios (HR) and 95% confidence intervals
(CI) were calculated for the outcomes defined above as a
function of NT-proBNP in crude models and models ad-
justed for demographics (age, race, sex, income, education,
geographic region of residence), Framingham risk factors
(smoking, systolic blood pressure, diabetes, HDL, total
cholesterol), and additional CVD risk factors (BMI, hsCRP,
ACR, eGFR, medications). NT-proBNP was analyzed in
tertiles with the lowest tertile serving as the reference
group. In the analysis accounting for incident fatal CHD
death, MI events followed by death within 28 days were
classified as CHD death, effectively comparing the associ-
ation between NT-proBNP and three separate outcomes:
nonfatal typical MI, nonfatal microsize MI, and fatal
CHD.
Because elevated BNP may be associated with HF, we
repeated all analyses excluding individuals with NT-
proBNP levels above the age-specific normal range (>
125 pg/mL if < 75 years old and > 450 pg/mL if ≥75 years
old), with an adjudicated HF hospitalization prior to
their MI event or CHD death, or who had HF during
the incident MI hospitalization.
In all analyses, a 2-tailed P value < 0.05 was considered
statistically significant. Additionally, 10% of individuals
had at least one missing value for covariates, thus final
analyses were conducted with multiple imputation using
chained equations [29]. Covariates with the largest
amount of missing values were ACR (4%) and hsCRP
(2%). Analyses were conducted using SAS software ver-
sion 9.4 (SAS Institute, Cary, NC) and Stata 14 (Stata
Corp, College Station, TX).
Results
Baseline characteristics of the study participants
Of the 30,239 REGARDS participants, we excluded 569
who were missing follow up, leaving 29,670 from which
1104 were drawn for the random sub-cohort. Of these, 50
were excluded for missing NT-proBNP, 23 for laboratory
inconsistencies, 182 for a history of CHD at baseline, and
2 on dialysis. A final analytic sub-cohort of 847 was used
for this analysis (Additional file 1: Fig. S1). Over a median
of 5.0 (IQR: 3.5, 6.3) years of follow-up time, there were
454 incident MI cases, of which 315 were typical MIs and
139 were microsize MIs. The median time to event for
microsize MI was 2.7 (IQR: 1.3, 5.5) and the median time
to event for typical MI was 2.2 (1.1, 3.7). There were also
195 incident fatal CHD cases. Twenty-one of the partici-
pants who experienced incident MI or fatal CHD were in
the randomly selected sub-cohort.
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Baseline characteristics of sub-cohort random sample
participants by tertile of NT-proBNP are shown in
Table 1. Higher NT-proBNP was characterized by female
sex, white race, older age, lower educational attainment,
lower annual income, higher risk factor levels, and a
greater burden of medical illness.
Associations of NT-proBNP with microsize and typical MIs
The cause-specific hazard ratios (CHR) for microsize
and typical MIs by tertile of NT-proBNP are shown in
Table 2. A significant difference in the association be-
tween NT-proBNP and the risk of microsize versus typ-
ical MI was seen in unadjusted and adjusted models (p
for equality = 0.03). In the unadjusted model, partici-
pants in the highest tertile of baseline NT-proBNP com-
pared to the lowest had higher risk of incident microsize
MI (CHR 7.06, CI: 3.96–12.57) compared to incident
typical MI (CHR 2.86, CI: 2.01–4.05). These results were
similar with full adjustment (NT-proBNP and microsize
MI adjusted CHR [aCHR] 6.83 (CI: 3.52–13.25) and
typical MI aCHR 2.63 (CI: 1.63–4.33) with a p for equal-
ity of 0.03 (Table 2).
In the sensitivity analysis of the competing risk be-
tween microsize and typical MI among participants
without possible HF, a total of 71 participants with
microsize MIs and 133 participants with typical MIs
were excluded. A significant difference in the risk of in-
cident microsize versus typical MI by NT-proBNP ter-
tiles persisted (p for equality = 0.05), with the association
between NT-proBNP and microsize MI remaining larger
across unadjusted and adjusted models, albeit of border-
line statistical significance (p for equality = 0.06)
(Table 3).
When accounting for acute fatal CHD as a competing
risk, a significant difference in the association between
NT-proBNP and risk of incident non-fatal microsize MI
versus non-fatal typical MI was detected in unadjusted
(p for equality < 0.01) and adjusted models (p for equal-
ity = 0.03) (Additional file 1: Table S1). In the unadjusted
analysis, participants in the highest tertile of baseline
NT-proBNP compared to the lowest tertile had higher
Table 1 Baseline Characteristics of Study Participants in the Cohort Random Sample by Tertiles of NT-proBNP
Brain Natriuretic Peptide (N-terminal pro BNP), tertiles of pg/mL
Characteristics* < 42.5 42.5–115.5 ≥115.5 p-value †
Total participants, n 278 ‡ 280‡ 289‡
Male, n (%) 168 (60.4) 119 (42.5) 101 (35.0) < 0.001
African American, n (%) 168 (56.8) 129 (46.1) 142 (49.1) 0.03
Age in years, mean (SD) 59.7 ± 9.5 65.9 ± 11.2 74.5 ± 10.9 < 0.001
Less than High School education, n (%) 28 (10.1) 38 (13.6) 61 (21.1) 0.001
Annual Income, n (%) 0.001
< $20,000 38 (13.7) 46 (16.4) 71(24.6)
≥$20,000 208 (74.8) 193 (68.9) 157 (54.3)
Declined to report 32 (11.5) 41 (14.6) 61 (21.1)
Current smoking, n (%) 46 (16.6) 41 (14.7) 33 (11.5) 0.21
Systolic blood pressure, mmHg, mean (SD) 125 ± 14.8 127 ± 17.4 130.8 ± 18.0 < 0.001
High density lipoprotein, mg/L, mean (SD) 50.0 ± 14.7 53.1 ± 17.0 54.0 ± 18.7 0.005
Total cholesterol, mg/L, mean (SD) 196 ± 41 192 ± 37 186 ± 37 < 0.001
Diabetes, n (%) 52 (19.1) 49 (17.8) 59 (20.6) 0.67
Body mass index, kg/m2, mean (SD) 29.8 ± 5.7 29.1 ± 6.5 27.6 ± 5.5 < 0.001
C-reactive protein mg/L, median (IQR) 1.9 [0.9–5.0] 2.1 [0.9–4.7] 2.2 [1.1–4.7] 0.37
Urinary albumin-to-creatinine ratio > 30 mg/g, n (%) 14 (5.1) 30 (11.2) 65 (23.6) < 0.001
Estimated glomerular filtration mL/min/1.73 m2 rate < 60§, n (%) 10 (3.6) 25 (9.0) 70 (24.5) < 0.001
Use of hypertensive medication, n (%) 112 (40.4) 128 (45.9) 173 (60.5) < 0.001
Use of statins, n (%) 73 (26.5) 69 (24.9) 78 (27.2) 0.82
Regular use of aspirin, n (%) 97 (35.0) 95 (34.0) 117 (40.6) 0.21
* Characteristics within the cohort random sample; missing values included use of statins (n = 7), use of hypertensive medication (n = 5), estimated glomerular filtration
rate (eGFR) (n = 7), baseline diabetes (n = 11), C-reactive protein (n = 23), aspirin use (n = 2), urinary albumin-to-creatinine ratio (n = 32), systolic blood pressure (n = 5),
high density lipoprotein (n = 13), cholesterol (n = 7), and body mass index (n = 7). † P-values from analysis of variance for continuous variables and Pearson chi square
for categorical variables. ‡ Data weighted to the full cohort for analysis. Tertiles based off of weighted sample. § eGFR < 60 mL/min/1.73 m2 = chronic kidney
disease (CKD)
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risk of incident non-fatal microsize MI (CHR 6.69, CI: 3.
69–12.12) than typical MI (CHR 2.57, CI: 1.80–3.67)
and incident fatal CHD (CHR 5.15, CI: 3.31–8.01). These
results were similar with full adjustment (NT-proBNP
and incident non-fatal microsize MI aCHR 6.07, CI: 3.
12–11.77; typical MI aCHR 2.25, CI: 1.41–3.60; and inci-
dent fatal CHD (aCHR 4.76, CI: 2.79–8.10).
In the sensitivity analysis accounting for fatal CHD
among those without possible HF, there were substan-
tially fewer events (Additional file 1: Table S2). Similar
to the main results, the unadjusted HR for non-fatal
microsize MI (HR 4.69 (95% CI 2.06–10.70) was higher
than for typical MI (HR 2.20 [95% CI 1.35–3.59]), but
this difference was not statistically significant. These pat-
terns were maintained after full adjustment, and were
also not statistically significant.
Discussion
In this prospective study of black and white US adults,
similar to past studies, NT-proBNP was strongly associ-
ated with MI, but we observed an even stronger associ-
ation between NT-proBNP and microsize MI than
typical MI. The greater association between NT-proBNP
and risk of microsize MI compared with typical MI
Table 2 Cause- Specific Hazard Ratios for Microsize MI and Typical MI according to Baseline Brain Natriuretic Peptide (NT-proBNP)
Tertiles
Events Microsize MI Events Typical MI P for equality a
Model 1
< 42.50(Ref) 16 1 73 1 0.03
42.5–115.5 46 3.11 (1.70–5.69) 97 1.41 (0.98–2.04)
≥ 115.50 77 7.06 (3.96–12.57) 145 2.86 (2.02–4.05)
Model 2
< 42.50(Ref) 16 1 73 1 0.03
42.5–115.5 46 3.18 (1.62–6.26) 97 1.26 (0.80–1.99)
≥ 115.5 77 6.83 (3.52–13.25) 145 2.66 (1.63–4.33)
Model 1 = BNP alone
Model 2 = Model 1 + Demographics (age, race, sex, household income, education, geographic region of residence), additional Framingham risk factors (current
smoking status, systolic blood pressure, diabetes, HDL and total cholesterol) and other CVD risk factors and covariates (body mass index, log-transformed hsCRP,
log-transformed ACR and medication use
All models tested for interactions of NT-proBNP with age, race and gender
Bold p < 0.05
a Cause specific model using Lunn and McNeil approach for competing risk analyses
Table 3 Cause- Specific Hazard Ratios for Microsize MI and Typical MI according to Baseline Brain Natriuretic Peptide (NT-proBNP)
Tertiles, Excluding Individuals with Possible Heart Failure (HF)
Events Microsize MI Events Typical MI P for equalitya
Model 1
< 42.5(Ref) 10 1 55 1 0.05
42.5–115.5 25 3.24 (1.68–6.30) 66 1.27 (0.87–1.87)
≥115.5 33 5.70 (2.65–12.29) 61 2.46 (1.53–3.94)
Model 2
< 42.50(Ref) 10 1 55 1 0.06
42.5–115.5 25 3.17 (1.46–6.85) 66 1.16 (0.70–1.92)
≥115.5 33 5.41 (2.14–13.69) 61 2.15 (1.07–4.32)
Possible heart failure (HF) defined as:
1. Baseline BNP > 125 if a participant is < than 75 years of age, or BNP > 450 if a participant ≥ 75 years
a. N = 362 among first sub-cohort (random sample, plus participants with CHD events)
b. N = 297 among second sub-cohort (random sample, plus participants with MI events)
2. Participants who had an incident MI event with concurrent prevalent HF (n = 18) and participants with MI and incident HF at the same date (n = 32)
3. Participants who had a first HF admission before an incident MI (n = 2)
Participants without MI event, but with incident HF before 01/01/2011 were censored at the time of first HF admission
Model 1 = BNP alone
Model 2 = Model 1 and Demographics (age, race, sex, household income, education, geographic region of residence), additional Framingham risk factors (current
smoking status, systolic blood pressure, diabetes, HDL and total cholesterol) and other CVD risk factors and covariates (body mass index, log-transformed hsCRP,
log-transformed ACR and medication use
Bold p < .05
aCause specific model using Lunn and McNeil approach for competing risk analyses
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persisted across multivariable models, in analyses ex-
cluding patients with potential HF, and analyses incorp-
orating incident fatal CHD. To our knowledge, this is
the first examination of the relationship of NT-proBNP
with microsize MI, an entity only recently recognized as
a large component of MIs in the modern era.
Increasingly sensitive troponin assays now routinely
detect very small, or microsize, MIs, [30–33] which
comprised 31.3% of non-fatal MI events in REGARDS
and have been found to be associated with long-term
CHD risk, apart from typical MIs [8]. Yet, due to vari-
ation across US laboratories, these very small events
may often be missed or misclassified [21]. Work by Mills
et al. (2011) suggests that misclassification may have ser-
ious clinical consequences: among patients presenting
with suspected acute coronary syndrome (ACS), lower-
ing the diagnostic threshold for MI from the previous
generation troponin assay cutoff (0.20 ng/mL) to 0.
05 ng/mL was associated with increased detection of
MIs by 29%, increased evidence-based treatment in the
group with peak troponin 0.05–0.20 ng/mL, and 50% re-
duction in death or recurrent MI among those with
these small events [12]. The percent rise in events in the
Mills study (29%) is remarkably similar to the proportion
of microsize MIs in the REGARDS study (31%). These
two studies, and others, [34, 35] demonstrate that failing
to recognize and potentially treat microsize MI events
could have profound implications for patient morbidity
and mortality.
To date, the clinical characteristics of individuals who
present with microsize MIs are not well described. We
found that baseline levels of NT-proBNP were more
strongly associated with risk of incident microsize MIs
compared to typical MIs, which suggests that microsize
MIs and typical MIs may differ with respect to their risk
factor profiles and possibly their underlying pathophysi-
ology. It is well known that myocardial stretch stimulates
the release of NT-proBNP; NT-proBNP levels are also
closely associated with vascular remodeling, inflammation,
and hypertrophy in the cardiovascular system [33, 36].
Local hypoxemia and ischemia, independent of changes in
left ventricular function, have been shown to induce NT-
proBNP synthesis [37–39] and following tissue injury, in-
flammatory cytokines [40, 41] and cardiac myocytes in-
duce BNP secretion as fibrosis [41] and vascular
remodeling occurs [42]. Given the extent to which we
found NT-proBNP to be associated with microsize MIs, it
is plausible that these small events occur in the context of
microvascular derangements of circulating factors in a
way that differs from the medium vessel atherosclerotic
plaque rupture that characterizes typical MIs. Recent
studies further support this hypothesis by demonstrating
that NT-proBNP levels are associated with small vessel
disease [43, 44]. Mutlu et al. (2016) reported that in
participants without cardiovascular disease, higher levels
of NT-proBNP were associated with microvascular dam-
age in the retina and retinal arterioles [45]. Additionally,
Bower et al. (2015) found that higher levels of NT-
proBNP were associated with incident hypertension, [46]
a process that involves arteriolar narrowing, increased car-
diac output, hypoxemia at the level of myocytes, and ul-
timately release of NT-proBNP. Finally, in a prospective
study, Cushman et al. (2016), found that higher NT-pro-
BNP levels were associated with incident cognitive impair-
ment, independent of CVD and Alzheimer’s disease risk
factors [16]. Together, these studies suggest that high
levels of NT-proBNP may occur alongside, or in response
to, systemic microvascular dysfunction in addition to, or
apart from, its known association with large vessel disease.
Our findings also have important implications for the
utility of NT-proBNP as a biomarker of CHD. A recent
individual-participant-data meta-analysis found that among
those without known baseline CVD, NT-proBNP concen-
tration predicted first-onset HF and improved the predic-
tion of CHD and stroke. [47] Additionally, the Dallas Heart
Study demonstrated an independent association between
coronary atherosclerosis burden and circulating levels of
NT-proBNP [48] in a large, low-risk population without
symptomatic HF or ischemia. NT-proBNP levels are inde-
pendently predictive of atherosclerotic events [49, 50];
Goyal et al. (2014) found that BNP levels are related to the
severity of coronary atherosclerosis such that patients with
multi-vessel disease had higher BNP levels than those with
one or two vessel involvement. Notably, this finding was in-
dependent of a diagnosis of unstable angina or NSTEMI.
Collectively, these findings, in addition to our finding that
NT-proBNP was strongly associated with both non-fatal
microsize MI and fatal CHD, suggest that NT-proBNP
might be used for risk stratification. However, it is import-
ant to note that major clinical trials in CHD have focused
almost exclusively on typical MIs. As such, additional work
is needed to identify the optimal clinical management strat-
egies for patients surviving a microsize MI event.
Strengths and limitations
This study’s strengths include the large, geographically and
racially diverse cohort in which participants were followed
prospectively. Baseline data were collected in standardized
fashion and prospective data included CHD endpoints ad-
judicated by expert clinicians. This study is unique in that
we were able to study microsize MI events, which have not
been specifically reported in other cohort studies and may
be difficult to capture in claims data. Finally, competing risk
analyses permitted examination of the association between
NT-proBNP and incident microsize MIs versus typical MIs
while accounting for acute fatal CHD.
Some limitations should be considered when interpret-
ing these findings. Only a single baseline measure of NT-
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proBNP was available, with varying elapsed time between
baseline and the events of interest. Only black and white
adults were included, potentially limiting generalizability
to other races or ethnicities. We were unable to measure
left ventricular ejection fraction (LVEF) among cases or
controls in this study; since ischemic and dilated cardio-
myopathies are often associated with elevated troponin
and NT-proBNP levels, future studies on the association
between NT-proBNP and microsize MIs ought to include
this as a covariate in multivariable models. Our sensitivity
analysis excluding those with possible HF to some extent
overcomes this limitation. Finally, several variables were
self-reported with known vulnerability to bias.
Conclusion
This is the first study to examine the association of NT-
proBNP with risk of microsize MI. Although baseline NT-
proBNP levels were associated with microsize MIs, typical
MIs, and fatal CHD, the association between NT-proBNP
and risk of incident microsize MI was markedly higher than
typical MI. This association persisted with adjustment for
demographic and clinical covariates, excluding participants
with possible HF, and accounting for fatal CHD. These re-
sults highlight the utility of NT-proBNP as a marker of
CHD events, particularly the entity of microsize MIs. Our
findings are concordant with past studies that suggest that
these very small events represent a large proportion of MI
events, but our findings build on these observations to sug-
gest that they may differ from typical MIs, particularly with
respect to risk factors and pathophysiology. Further study is
needed to understand the relative contribution of trad-
itional and non-traditional risk factors to the incidence of
microsize MIs compared to typical MIs, as well as to
understand differences in outcomes. If there are sufficient
differences, it is possible that separate risk stratification
tools may be needed, and NT-proBNP may be a candidate
for inclusion in such tools. Our findings underscore that a
better understanding is needed of this very large proportion
of MIs in the modern era.
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